Aims: To compare real-world antidiabetic treatment outcomes over 12 months in obese people with type 2 diabetes mellitus (T2DM) who previously received oral antidiabetic therapy and then initiated a first injectable therapy with liraglutide or basal insulin. Results: Obese patients with T2DM (N = 1157) in each treatment group were matched (liraglutide cohort, n = 544; BOT cohort, n = 613). From 3 months onwards, glycaemic control improved in both cohorts but improved significantly more with liraglutide than with BOT (12 months: −12.2 mmol/mol vs −8.8 mmol/mol; P = .0053). In addition, weight and BMI were significantly lower for treatments with liraglutide vs BOT (12 months: −6.0 kg vs −1.6 kg and − 2.1 kg/m 2 vs −0.5 kg/m 2 , respectively; P < .0001 for both). No significant differences were seen in changes in cardiovascular risk factors.
| INTRODUCTION
In 2013, 56 million people were diagnosed with diabetes in Europe, with a further increase of 10 million projected by 2035. 1 Diabetes is associated with disability and is a major cause of premature mortality. 2 Compared with that in the general population, the risk of coronary heart disease is 2 to 4 times higher in men and women with type 2 diabetes mellitus (T2DM), respectively. 3 Half of people with T2DM die prematurely from a cardiovascular cause, while~10% die from renal failure. Compared with non-overweight people, overweight and obese people with T2DM are at an even greater risk of coronary heart disease, stroke, cardiovascular disease and all-cause mortality, 4 and their weight negatively impacts their lives and perception of health status. 5 Diabetes is therefore one of the world's leading causes of healthcare expenditure and of economic loss in society. The American Diabetes Association (ADA) calculated that people with diabetes have healthcare expenditure 2.3 times higher than that for the same population without diabetes. 6 While the care for people with diabetes who experience macro-and microvascular complications is particularly costly to the healthcare system 7, 8 ; metabolic complications may explain~11%
of the extra costs of the disease. 6 In the Netherlands, the total economic burden of diabetes was calculated to be €6.8 bn in 2016. 9 More than half (~€4.0 bn) of these costs are indirect and are related to productivity losses, welfare payments and complications, with another €2.9 bn spent on disease care and treatment of complications.
In a joint position paper, both the ADA and the European Association for the Study of Diabetes have recommended a stepwise addition of one of five classes of anti-hyperglycaemic drugs to metformin when patients fail to achieve their glycated haemoglobin (HbA1c) target. 10, 11 When considering pharmacological treatments for obese patients with T2DM, it is suggested that medications should be chosen to promote weight loss or to be weight-neutral, to improve insulin resistance and to reduce blood pressure and blood lipid levels. 12, 13 Fear of weight gain and hypoglycaemia are risk factors known to delay intensification of antidiabetic treatment. 14, 15 Obtaining tight glycaemic control with certain antidiabetic medications, particularly insulin and sulphonylureas, may paradoxically be accompanied by an increased risk of weight gain and hypoglycaemia, 16 Although RCTs provide evidence of the efficacy and safety of diabetes treatments, these trials are limited by their design, setting and patient characteristics. Hence, the results cannot be generalized directly to the real-world clinical setting. 18 An evidence gap exists, therefore, between RCTs and real-world practice that warrants studies using real-world data. 
| Study population
From the Out-patient Pharmacy Database, data from patients using liraglutide or BOT were included based on the following inclusion cri- Changes in concomitant OAD drugs were allowed in both cohorts.
A series of steps were followed to select eligible patients and form two matched cohorts of patients receiving either liraglutide or BOT ( Figure 1 ). Propensity score matching was performed to minimize selection bias attributable to the more restrictive reimbursement conditions for GLP-1RAs than for BOT. 21 
| Study cohort definition
To ensure comparable treatment cohorts and to include as many patients as possible, selected liraglutide and BOT users were matched per outcome, resulting in eight matched cohorts. Matching (ratio 1:1) was based on propensity scores determined with logistic regression modelling with categorical variables (Table S1 ) in order to allow the contribution of clinical variables that were not known for all patients, but were not the main outcome of interest. Variables significantly associated with the probability of receiving liraglutide (univariate type III P < .05) were included in a backward selection process, retaining the variables that were significantly associated in the multivariate model (P < .05). Age was always included in the propensity score. The variable "concomitant OAD treatment at start of liraglutide or BOT" was an exact matching criterion outside the scope of the propensity score.
Patients were matched on the logit of the propensity score using callipers with a width equal to 0.2 of the standard deviation (SD). The HbA1c targets were ≤53 mmol/mol (≤7.0%) for patients aged <70 years, ≤58 mmol/mol (≤7.5%) for older patients with a diabetes duration <10 years, and ≤64 mmol/mol (≤8%) for all remaining patients. 20 The proportion of patients reaching their HbA1c target was assessed per 3-month interval. For missing time points, the last observation was carried forward until the next available time point or the end of follow-up for each patient.
| Statistical analysis
All data were analysed using SAS programs in SAS Enterprise Guide version 7.1 (SAS Institute Inc., Cary, NC, USA) and conducted in Windows using SAS version 9.4. Figure S1 , the logit of the propensity score distribution is given for HbA1c, weight and BMI.
| RESULTS

Between
| Demographic and clinical characteristics of the studied cohorts
Patient demographics and their clinical characteristics for the HbA1c outcomes are shown in Table S2 and Figure S2 ).
The proportion of patients reaching their individual HbA1c target in the liraglutide cohort and the BOT cohort increased from 16% and 11%, respectively, at baseline to 57% and 33%, respectively, at 3 months. At 12 months, the difference still existed, with 45% of the patients in the liraglutide cohort and 38% in the BOT cohort reaching their target HbA1c (Table 3) .
| Weight and BMI values
In the liraglutide cohort, mean weight declined over time, while a minimal decline was observed in the BOT cohort (Table 2 and Figure 2) .
The difference in weight change between the liraglutide cohort and the BOT cohort was statistically significant at 12 months (−6.0 vs −1.6 kg; P < .0001) and at 18 months (−5.3 vs −0.6 kg; P < .0001 [- Table S2 and Figure S2] ).
The mean change in BMI from baseline in the liraglutide cohort steadily decreased, reaching a mean reduction of −2.1 kg/m 2 at 12 months (Table 2 and Figure 2 ). In the BOT cohort, BMI declined by −0.6 kg/m 2 at 3 months with no change at subsequent time points.
Consequently, the differences between the cohorts increased at each time point and reached significance at 6 (P = .0051), 9 and 12 months (P < .0001). These findings persisted at 15 months, the 50% attrition time point (Table S2 and Figure S2 ).
| Cardiovascular risk biomarkers
The mean changes from baseline and mean differences in change from baseline between cohorts for several cardiovascular risk biomarkers, including SBP, DBP, total cholesterol, HDL cholesterol and LDL cholesterol, are summarized in Table S3 and Figures S3 and S4. The trends over time for SBP and DBP in both cohorts fluctuated and were not significantly different between cohorts. In both cohorts, the lipid levels changed slightly over time, with no statistically significant differences between cohorts. For all cardiovascular biomarkers, the trends persisted at the 50% attrition time point (Table S3 and Figures S3 and S4 ). Abbreviations: BMI, body mass index; BOT, basal insulin supported oral therapy; HbA1c, haemoglobin A1c; kg, kilograms; LSM, least square mean; 95% CI, 95% confidence interval.
| DISCUSSION
The results of the present study show that initiating liraglutide, 
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To our knowledge, this study comparing the effectiveness of liraglutide and BOT in two propensity score-matched T2DM cohorts of obese patients is the first of its kind. Only in the early pilot phase of the INITIATOR study was a real-world comparison made between liraglutide and insulin glargine in a cohort of patients with T2DM. 25 That study showed no difference in HbA1c between liraglutide and insulin FIGURE 2 Least squares mean (LSM) changes from baseline in glycated haemoglobin (HbA1c, mmol/mol), weight (kg) and body mass index (BMI, kg/m 2 ) at 3, 6, 9 and 12 months after treatment initiation in the liraglutide and BOT cohorts. BOT: basal insulin supported oral therapy; 95% CI, 95% confidence interval glargine (weight was not captured) after 9 months of treatment; however, matching was not applied, resulting in significant baseline differences between the study groups. 25 In the present study, 70 patients were lost in the primary outcome analysis because of a lack of overlap in matching criteria, indicating that the liraglutide and BOT populations were indeed very different, and matching was imperative for comparison between cohorts.
Nearly 50% of the patients on liraglutide maintained the HbA1c goal levels at 12 months. This sustained optimization of the T2DM; these two beneficial effects seem to be more pronounced with liraglutide than with other GLP-1RAs. 24, 26 It should also be mentioned that weight changes in the order of a 5% loss lead to decreased insulin resistance and improved glycaemic levels. 23 In the present real-world study, small changes in cardiovascular risk biomarkers, such as blood pressure or lipids, were found, with non-significant differences between patients on liraglutide and BOT. showing that liraglutide significantly improves the levels of total cholesterol, LDL cholesterol, free fatty acids, and triglycerides to a small extent. 23 Data from the LEADER trial show that treatment with liraglutide leads to a significant reduction in cardiovascular risk in patients with T2DM and a high risk of cardiovascular events. 27 Early evidence from the United Kingdom Prospective Diabetes Study found that a 1% decrease in mean HbA1c (ie, 11 mmol/mol) was associated with a statistically significant risk reduction for heart failure, myocardial infarction and stroke. 28 More recent data from population-based studies also showed that achievement of desirable HbA1c levels within 6 months of treatment initiation or adjustment was associated with a lower risk of myocardial infarction or stroke and death in patients with T2DM. 29 Another cohort study conducted in obese people with T2DM from the UK showed that adding a GLP-1RA was associated with a greater decrease in the risk of major adverse cardiovascular events than adding insulin therapy as the third glucose-lowering agent. 30 Furthermore, decreasing cardiovascular risk, reducing weight and avoiding hypoglycaemia are the attributes of treatments that are most valued by people with T2DM. 31 These aspects are of crucial importance in treatment decision-making because their consideration may improve adherence and persistence, which are both needed to achieve the expected clinical benefits. 32 The results of the present study should be interpreted in the context of several limitations. First, the study was based on data from a Dutch population sample, therefore, the findings may not be representative of inhabitants of other countries, especially taking into account the specific Dutch reimbursement restrictions (mandatory specialist prescribing, failed oral alternatives, BMI ≥35 kg/m 2 ). Second, information on patients' T2DM history, hypoglycaemia, heart rate, comorbidities, changes in OAD co-medications, and other factors that may determine the response to treatments were not accounted for during follow-up or at the end the of study (Table 1 ). In addition, in this real-world study, possible side effects of the therapies could not be evaluated. Databases such as the PHARMO Database Network do not provide the level of clinical detail that is available in secondary care outpatient medical records. The information available on the patients eligible for this study was therefore restricted to the type of data provided in the database. Third, database studies can establish only associations and not cause-and-effect relationships, although inferential analyses were performed. Fourth, propensity score matching is a well-recognized statistical technique that allows the design and analysis of real-world studies while mimicking some of the characteristics of an RCT. The propensity score is a balancing score: conditional on this score, the distribution of observed baseline characteristics will be similar between treated and untreated patients, for instance. 33 Sample matching based on propensity scores, however, has some limitations. The number of patients in the matched final sample might be reduced substantially, and this possibility should be balanced with the need to maintain statistical power. Another drawback is that two completely unrelated factors in the model may result in a similar propensity score. Additionally, a correlation between factors in the propensity score model may have the undesired effect that a HbA1c targets were ≤53 mmol/mol (≤7.0%) for patients aged <70 years, ≤58 mmol/mol (≤7.5%) for older patients with a diabetes duration <10 years, and ≤64 mmol/mol (≤8%) for all remaining patients.
b Patients still on treatment during interval.
Abbreviations: BOT, basal insulin supported oral therapy; HbA1c, haemoglobin A1c.
differences between less predictive characteristics may actually increase. In the present study, the varying strengths of the associations of variables in the propensity model sometimes augmented differences in characteristics that were less predictive for receiving GLP1RAs (eg, weight was much stronger than age, but age was associated with weight). Further refinement of the matching procedures to reduce these differences resulted in fewer matched patients and thus a lack of power; therefore, these remaining differences in variable distributions were permitted and further adjusted for in the comparative analyses models. Finally, it was assumed that patients took their medicines as dispensed and followed medical recommendations on dosing and frequency. The effect of poor adherence to treatments was not evaluated, which may have affected the outcome measures.
Nevertheless, the study relied on an updated, large and compre- 
